Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: Sadif Analytics Prime
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stallergenes SA expands Latin American presence with acquisition of ALERGO PHARMA S.R.L

Monday, 21 Jul 2014 01:20pm EDT 

Stallergenes SA:Says acquisition of entire share capital of ALERGO PHARMA S.R.L., an Argentinean allergen immunotherapy (AIT) company.Aim of acquisition is to combine two complementary dedicated allergen immunotherapy companies, working together to provide a more comprehensive and broader range of diagnosis and treatment solutions to patients suffering from allergic respiratory diseases.This acquisition establishes STALLERGENES among top allergen immunotherapy pharmaceutical companies in Latin America further broadening STALLERGENES' geographic presence across the region.Terms of transaction are not disclosed. 

Company Quote

-0.16 -0.32%
11:35am EST